APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Analysis and Forecast 2026-2032

Report ID 17421468031 May 2026214 pages

Choose your research edition.

Industry ResearchPharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service include SGS, Quanticate, Mercodia, Creative Biolabs, Allucent, IRBM, Pacific BioLabs, Altasciences and Celerion, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service revenue, projected growth trends, production technology, application and end-user industry.

Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Company

SGS

Quanticate

Mercodia

Creative Biolabs

Allucent

IRBM

Pacific BioLabs

Altasciences

Celerion

Labcorp

Oncodesign Services

Drug Development Solutions

CD BioSciences

Creative-Bioarray

Biotrial

Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Type

In Vivo PK and PD Service

PK and PD modelling

DMPK Analysis

Ligand-Binding

Others

Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Application

Pharmaceutical Company

Research Institute

Others

Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. In Vivo PK and PD Service Major Player Table 3. PK and PD modelling Major Player Table 4. DMPK Analysis Major Player Table 5. Ligand-Binding Major Player Table 6. Others Major Player Table 7. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Pharmaceutical Company Major Player Table 9. Research Institute Major Player Table 10. Others Major Player Table 11. Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Trends Table 12. Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Drivers Table 13. Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Opportunities and Challenges Table 14. Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Restraints Table 15. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Share by Region (2021-2026) Table 18. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Share by Region (2027-2032) Table 20. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Players (2021-2026) Table 22. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Key Players Headquarters & Area Served Table 24. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players, Product Type & Application Table 25. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Type (2021-2026) Table 32. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Type (2027-2032) Table 33. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Application (2021-2026) Table 37. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Application (2027-2032) Table 38. SGS Company Information Table 39. SGS Business Overview Table 40. SGS Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. SGS Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 42. SGS Recent Development Table 43. Quanticate Company Information Table 44. Quanticate Business Overview Table 45. Quanticate Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Quanticate Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 47. Quanticate Recent Development Table 48. Mercodia Company Information Table 49. Mercodia Business Overview Table 50. Mercodia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Mercodia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 52. Mercodia Recent Development Table 53. Creative Biolabs Company Information Table 54. Creative Biolabs Business Overview Table 55. Creative Biolabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Creative Biolabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 57. Creative Biolabs Recent Development Table 58. Allucent Company Information Table 59. Allucent Business Overview Table 60. Allucent Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Allucent Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 62. Allucent Recent Development Table 63. IRBM Company Information Table 64. IRBM Business Overview Table 65. IRBM Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. IRBM Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 67. IRBM Recent Development Table 68. Pacific BioLabs Company Information Table 69. Pacific BioLabs Business Overview Table 70. Pacific BioLabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Pacific BioLabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 72. Pacific BioLabs Recent Development Table 73. Altasciences Company Information Table 74. Altasciences Business Overview Table 75. Altasciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Altasciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 77. Altasciences Recent Development Table 78. Celerion Company Information Table 79. Celerion Business Overview Table 80. Celerion Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Celerion Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 82. Celerion Recent Development Table 83. Labcorp Company Information Table 84. Labcorp Business Overview Table 85. Labcorp Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Labcorp Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 87. Labcorp Recent Development Table 88. Oncodesign Services Company Information Table 89. Oncodesign Services Business Overview Table 90. Oncodesign Services Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Oncodesign Services Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 92. Oncodesign Services Recent Development Table 93. Drug Development Solutions Company Information Table 94. Drug Development Solutions Business Overview Table 95. Drug Development Solutions Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Drug Development Solutions Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 97. Drug Development Solutions Recent Development Table 98. CD BioSciences Company Information Table 99. CD BioSciences Business Overview Table 100. CD BioSciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. CD BioSciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 102. CD BioSciences Recent Development Table 103. Creative-Bioarray Company Information Table 104. Creative-Bioarray Business Overview Table 105. Creative-Bioarray Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Creative-Bioarray Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 107. Creative-Bioarray Recent Development Table 108. Biotrial Company Information Table 109. Biotrial Business Overview Table 110. Biotrial Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Biotrial Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio Table 112. Biotrial Recent Development Table 113. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026) & (US$ Million) Table 119. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (US$ Million) & (2027-2032) Table 120. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 123. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 124. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (US$ Million) & (2027-2032) Table 127. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 128. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 129. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 130. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 132. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 133. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 134. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Region (US$ Million) & (2021-2026) Table 137. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Region (US$ Million) & (2027-2032) Table 138. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 139. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 140. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 141. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 142. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026) & (US$ Million) Table 144. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (US$ Million) & (2027-2032) Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Image Figure 2. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. In Vivo PK and PD Service Image Figure 5. PK and PD modelling Image Figure 6. DMPK Analysis Image Figure 7. Ligand-Binding Image Figure 8. Others Image Figure 9. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size Share 2021 VS 2025 VS 2032 Figure 11. Pharmaceutical Company Image Figure 12. Research Institute Image Figure 13. Others Image Figure 14. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size (US$ Million) & (2021-2032) Figure 15. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Type (2021-2032) Figure 22. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Application (2021-2032) Figure 25. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032) Figure 27. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032) Figure 28. North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Country (2021-2032) Figure 29. United States Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032) Figure 34. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032) Figure 35. Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Country (2021-2032) Figure 36. Germany Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032) Figure 46. China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032) Figure 47. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032) Figure 49. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032) Figure 50. Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Region (2021-2032) Figure 51. Japan Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032) Figure 59. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032) Figure 60. SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Country (2021-2032) Figure 61. Brazil Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • In Vivo PK and PD Service
  • PK and PD modelling
  • DMPK Analysis
  • Ligand-Binding
  • Others
Applications
  • Pharmaceutical Company
  • Research Institute
  • Others
Companies covered
  • SGS
  • Quanticate
  • Mercodia
  • Creative Biolabs
  • Allucent
  • IRBM
  • Pacific BioLabs
  • Altasciences
  • Celerion
  • Labcorp
  • Oncodesign Services
  • Drug Development Solutions
  • CD BioSciences
  • Creative-Bioarray
  • Biotrial

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market by Type
  3. 1.2.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 In Vivo PK and PD Service
  5. 1.2.3 PK and PD modelling
  6. 1.2.4 DMPK Analysis
  7. 1.2.5 Ligand-Binding
  8. 1.2.6 Others
  9. 1.3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market by Application
  10. 1.3.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Pharmaceutical Company
  12. 1.3.3 Research Institute
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Dynamics
  1. 2.1 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Trends
  2. 2.2 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Drivers
  3. 2.3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Opportunities and Challenges
  4. 2.4 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Perspective (2021-2032)
  2. 3.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Growth Trends by Region
  3. 3.2.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Players
  2. 4.1.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Key Players Headquarters & Area Served
  7. 4.4 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players, Product Type & Application
  8. 4.5 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market CR5 and HHI
  11. 4.6.3 2025 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Tier 1, Tier 2, and Tier 3
5 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Type
  1. 5.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2032)
  3. 5.3 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Type (2021-2032)
6 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Application
  1. 6.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2032)
  3. 6.3 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 SGS
  2. 7.1.1 SGS Company Information
  3. 7.1.2 SGS Business Overview
  4. 7.1.3 SGS Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 SGS Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  6. 7.1.5 SGS Recent Developments
  7. 7.2 Quanticate
  8. 7.2.1 Quanticate Company Information
  9. 7.2.2 Quanticate Business Overview
  10. 7.2.3 Quanticate Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Quanticate Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  12. 7.2.5 Quanticate Recent Developments
  13. 7.3 Mercodia
  14. 7.3.1 Mercodia Company Information
  15. 7.3.2 Mercodia Business Overview
  16. 7.3.3 Mercodia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mercodia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  18. 7.3.5 Mercodia Recent Developments
  19. 7.4 Creative Biolabs
  20. 7.4.1 Creative Biolabs Company Information
  21. 7.4.2 Creative Biolabs Business Overview
  22. 7.4.3 Creative Biolabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Creative Biolabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  24. 7.4.5 Creative Biolabs Recent Developments
  25. 7.5 Allucent
  26. 7.5.1 Allucent Company Information
  27. 7.5.2 Allucent Business Overview
  28. 7.5.3 Allucent Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Allucent Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  30. 7.5.5 Allucent Recent Developments
  31. 7.6 IRBM
  32. 7.6.1 IRBM Company Information
  33. 7.6.2 IRBM Business Overview
  34. 7.6.3 IRBM Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 IRBM Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  36. 7.6.5 IRBM Recent Developments
  37. 7.7 Pacific BioLabs
  38. 7.7.1 Pacific BioLabs Company Information
  39. 7.7.2 Pacific BioLabs Business Overview
  40. 7.7.3 Pacific BioLabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pacific BioLabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  42. 7.7.5 Pacific BioLabs Recent Developments
  43. 7.8 Altasciences
  44. 7.8.1 Altasciences Company Information
  45. 7.8.2 Altasciences Business Overview
  46. 7.8.3 Altasciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Altasciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  48. 7.8.5 Altasciences Recent Developments
  49. 7.9 Celerion
  50. 7.9.1 Celerion Company Information
  51. 7.9.2 Celerion Business Overview
  52. 7.9.3 Celerion Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Celerion Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  54. 7.9.5 Celerion Recent Developments
  55. 7.10 Labcorp
  56. 7.10.1 Labcorp Company Information
  57. 7.10.2 Labcorp Business Overview
  58. 7.10.3 Labcorp Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Labcorp Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  60. 7.10.5 Labcorp Recent Developments
  61. 7.11 Oncodesign Services
  62. 7.11.1 Oncodesign Services Company Information
  63. 7.11.2 Oncodesign Services Business Overview
  64. 7.11.3 Oncodesign Services Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Oncodesign Services Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  66. 7.11.5 Oncodesign Services Recent Developments
  67. 7.12 Drug Development Solutions
  68. 7.12.1 Drug Development Solutions Company Information
  69. 7.12.2 Drug Development Solutions Business Overview
  70. 7.12.3 Drug Development Solutions Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Drug Development Solutions Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  72. 7.12.5 Drug Development Solutions Recent Developments
  73. 7.13 CD BioSciences
  74. 7.13.1 CD BioSciences Company Information
  75. 7.13.2 CD BioSciences Business Overview
  76. 7.13.3 CD BioSciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 CD BioSciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  78. 7.13.5 CD BioSciences Recent Developments
  79. 7.14 Creative-Bioarray
  80. 7.14.1 Creative-Bioarray Company Information
  81. 7.14.2 Creative-Bioarray Business Overview
  82. 7.14.3 Creative-Bioarray Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Creative-Bioarray Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  84. 7.14.5 Creative-Bioarray Recent Developments
  85. 7.15 Biotrial
  86. 7.15.1 Biotrial Company Information
  87. 7.15.2 Biotrial Business Overview
  88. 7.15.3 Biotrial Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Biotrial Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
  90. 7.15.5 Biotrial Recent Developments
8 North America
  1. 8.1 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue (2021-2032)
  2. 8.2 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032)
  5. 8.3 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032)
  9. 8.5 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country
  11. 8.6.1 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue (2021-2032)
  2. 9.2 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032)
  5. 9.3 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032)
  9. 9.5 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country
  11. 9.6.1 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue (2021-2032)
  2. 10.2 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2032)
  3. 10.2.1 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026)
  4. 10.2.2 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032)
  5. 10.3 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032)
  6. 10.4 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2032)
  7. 10.4.1 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026)
  8. 10.4.2 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032)
  9. 10.5 China Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue (2021-2032)
  2. 11.2 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032)
  5. 11.3 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032)
  9. 11.5 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country
  11. 11.6.1 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue (2021-2032)
  2. 12.2 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country
  11. 12.6.1 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst